--- title: "Eledon Pharmaceuticals (ELDN.US) — Financial Reports" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ELDN.US/norm.md" symbol: "ELDN.US" name: "Eledon Pharmaceuticals" parent: "https://longbridge.com/en/quote/ELDN.US.md" datetime: "2026-05-22T00:03:02.249Z" locales: - [en](https://longbridge.com/en/quote/ELDN.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ELDN.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ELDN.US/norm.md) --- # Eledon Pharmaceuticals (ELDN.US) — Financial Reports ## Income Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | EPS | -0.3468 | -0.1088 | -0.2259 | -0.1454 | -0.0841 | | ROE | -131.60% | -36.68% | -70.87% | -54.41% | -29.35% | | Revenue | - | - | - | - | - | | Net income | -39.02M | -10.45M | -17.46M | -11.22M | -6.50M | | Operating income | -21.18M | -21.48M | -19.07M | -24.73M | -17.96M | | Gross margin | - | - | - | - | - | | Net margin | - | - | - | - | - | | Profit quality | - | - | - | - | - | ## Balance Sheet (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | A&L | 146.67M | 169.01M | 129.86M | 144.91M | 161.31M | | Leverage | 1.46 | 1.24 | 1.43 | 1.37 | 1.41 | | BVPS | 1.32 | 1.81 | 1.52 | 1.77 | 0.9815 | | Turnover | - | - | - | - | - | | Cash & STI | 111.09M | 133.34M | 93.40M | 107.57M | 124.88M | | Inv & Rec | - | - | - | - | - | | LT assets | 530000.00 | 613000.00 | 694000.00 | 773000.00 | 850000.00 | | Net debt | -110.53M | -132.69M | -92.68M | -106.77M | -124.00M | ## Cash Flow Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | Operating CF | -22.61M | -14.09M | -14.48M | -17.71M | -16.06M | | Investing CF | 5.96M | -20.46M | 12.40M | 14.96M | 3.89M | | Financing CF | - | 53.69M | 0.0000 | 0.0000 | 115000.00 | | Free CF | -16.07M | -6.38M | -7.99M | -9.24M | -10.05M | | OCF coverage | - | - | - | - | - | | Repaid & issued | - | - | - | - | - | | CapEx | - | - | - | - | - |